Drug
Anti Thymocyte Globulin
Anti Thymocyte Globulin is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_2
2
67%
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Not yet recruiting1
Recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 22 (66.7%)
Phase 41 (33.3%)
Trials by Status
not_yet_recruiting133%
recruiting133%
completed133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_2
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
NCT03630211
not_yet_recruitingphase_2
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
NCT05303727
completedphase_4
SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
NCT01266148
Clinical Trials (3)
Showing 3 of 3 trials
NCT03630211Phase 2
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
NCT05303727Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
NCT01266148Phase 4
SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3